NCT01393483Completed
Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)
A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)
Source: ClinicalTrials.gov · Last updated 28 Oct 2024
Brief summary (registry, in English)
The purpose of this study is to find out whether a protein, called mesothelin, found in the blood and tissue can be used as "marker" for esophageal cancer. Doctors at Memorial Sloan-Kettering Cancer Center would like to compare levels of this protein in patients with abnormal cells or tissue of the esophageal to the levels of this protein in patients being treated for cancer for the esophagus.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 371 (actual)
- First submitted
- 11 Jul 2011
- Start date
- Mar 2011
- Primary completion date
- 22 Oct 2024
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT01393483
What you commit to
- Study type: Observational
- Participants enrolled: 371
- From Mar 2011 to the primary completion date, 22 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients unfit medically for endoscopy surveillance and therapy
- Patients previously treated with chemo-radiotherapy for their esophageal cancer
Other illness
- Patients who have a history of cancer within 3 years or have a concurrent cancer.
Age
- Patients \<18 years of age
Other
- Patients unfit medically for esophagectomy
- Patients with stage IV esophageal adenocarcinoma
- Patients with squamous cell carcinoma of the esophagus
Who the study is looking for
- Patients with T1 adenocarcinoma or suspected adenocarcinoma who are scheduled for a biopsy and mucosal resection (Group 1)
- Patients with a T1-2N0 adenocarcinoma or suspected adenocarcinoma who are scheduled to undergo and esophagectomy (Group 2)
- Patients with T2N1 and T3N0-1 adenocarcinoma or suspected adenocarcinoma who are scheduled to undergo endoscopy and biopsy and/or endoscopic ultrasound and biopsy prior to pre-operative chemo-radiotherapy and have baseline and surgical tissue available for staining (Group 3)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.